Beam Therapeutics Q3 2026 net loss widens 19% to $134.41 million
Bitget2026/11/03 12:13- Beam Therapeutics’ third-quarter 2026 net loss widened 19% year over year to $134.41 million.
- License and collaboration revenue fell 97% to $307,000, while general and administrative expenses rose 18% to $31.52 million year over year.
- September-end cash, cash equivalents and marketable securities totaled $1.04 billion; projected runway into mid-2029 assumes additional borrowing.
- A U.S. biologics license application for sickle cell therapy risto-cel is expected as early as year-end 2026.
- Completion of dosing in BEAM-302’s global pivotal cohort for alpha-1 antitrypsin deficiency is expected in the first half of 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Amid opposition to data centers, Musk doubles down: SpaceX (SPCX.US) plans to build a $24 billion computing center and gas power plant in Texas.
According to a public hearing notice published on the Starbase website, SpaceX plans to build, own, and operate a gas-fired power plant and a supercomputing facility at its company town in Starbase, Texas.
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
Crypto prices
More
